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Parenteral oestrogen in the treatment of prostate cancer:
a systematic review
G Norman1, ME Dean1, RE Langley2, ZC Hodges1, G Ritchie1, MKB Parmar2, MR Sydes2, P Abel3
and AJ Eastwood*,1
1Centre for Reviews and Dissemination, University of York, York YO10 5DD, UK; 2Cancer Group, MRC Clinical Trials Unit, 222 Euston Road, London
NW1 2DA, UK; 3Hammersmith Campus, Department of Surgery, Imperial College Faculty of Medicine, London W12 0NN, UK
The objectives of this study were to assess the effectiveness and safety of parenteral oestrogen in the treatment of prostate cancer,
and to examine any dose relationship. A systematic review was undertaken. Electronic databases, published paper and internet
resources were searched to locate published and unpublished studies with no restriction by language or publication date. Studies
included were randomised controlled trials of parenteral oestrogen in patients with prostate cancer; other study designs were also
included to examine dose–response. Study selection, appraisal, data extraction and quality assessment were performed by one
reviewer and independently checked by another. Twenty trials were included in the review. The trials differed with regard to the
included patients, formulation and dose of parenteral oestrogen, comparator used, outcome measures reported and the duration of
follow-up. The results provide no evidence to suggest that parenteral oestrogen, in doses sufficient to produce castrate levels of
testosterone, is less effective than luteinising hormone-releasing hormone (LHRH) or orchidectomy in controlling prostate cancer, or
that it is consistently associated with an increase in cardiovascular mortality. Further well-conducted trials of parenteral oestrogen are
required. A pilot randomised controlled trial comparing transdermal oestrogen to LHRH analogues in men with locally advanced or
metastatic prostate cancer is underway in the United Kingdom.
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Prostate cancer is now the most common male cancer, with nearly
35 000 new cases in the United Kingdom in 2004 (Cancer Research
UK, 2007). When prostate cancer is not amenable to potentially
curative therapy, the aim of treatment is to reduce circulating
levels of androgens and/or block them from initiating intracellular
signalling. This can be achieved either surgically (by orchidect-
omy) or medically (referred to as androgen deprivation therapy
(ADT), e.g., by luteinising hormone-releasing hormone (LHRH)
analogues with or without anti-androgens).
Androgen deprivation therapy is now used extensively and for
prolonged periods of time, and concerns are increasing about
long-term toxicity, particularly osteoporosis. For example, a recent
longitudinal study has shown that 35% of men who received LHRH
therapy for prostate cancer will experience at least one skeletal
fracture in the first 7 years and 19% will be diagnosed with
osteoporosis/osteopaenia (Krupski et al, 2004). A number of
clinical trials are underway to address whether adding a bone-
strengthening agent, such as a bisphosphonate, to LHRH therapy
would decrease the incidence of osteoporosis and other skeletal-
related events. Several other side effects of castration, including
hot flushes, anaemia, and metabolic syndrome, are also increas-
ingly recognised, although others such as cognitive dysfunction
require further research to clarify their impact (Sharifi et al, 2005).
It has recently been suggested that the use of ADT is associated
with earlier onset of fatal myocardial infarction in men aged 65
years or above (D’Amico et al, 2007) and that in patients with
locoregional prostate cancer it may be associated with an increase
risk of cardiovascular disease not seen with orchidectomy (Keating
et al, 2006). An alternative approach is to evaluate agents that are
potentially as effective as, or more effective than, LHRH analogues
in activity, for example, by achieving castrate levels of testosterone
while avoiding some of the side effects of the castration syndrome.
Oral oestrogen therapy, such as diethylstilboestrol (DES), has
been used as a method of ADT and is reported to be as effective as
surgical orchidectomy or LHRH analogues in producing castrate
levels of testosterone (Byar, 1973). It also avoids some of the side
effects associated with the castration syndrome such as osteo-
porosis, osteoporotic fractures and hot flushes. However, large
randomised studies highlighted the cardiovascular system (CVS)
toxicities associated with this form of therapy, which occurred in
30–35% of patients treated with the highest doses (Byar, 1973).
The CVS side effects of oral oestrogen have been attributed to first-
pass hepatic metabolism (von Schoultz et al, 1989). In contrast,
parenteral oestrogen (e.g., administered intravenously, intramus-
cularly or transdermally) avoids first-pass metabolism in the
hepatic circulation system and is not expected to be associated
with the same incidence of CVS toxicity.
Two small pilot studies have been conducted evaluating
oestrogen patches for patients with prostate cancer (Ockrim
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et al, 2003; Morganstein et al, 2004). Neither study reported any
serious adverse events, and minor adverse effects such as skin
irritation were insufficient to cause discontinuation of treatment.
In light of concerns about osteoporosis from current methods of
ADT and preliminary evidence that oestrogen patches might be a
useful therapy, a systematic review was undertaken. The aim of
this review was to assess the existing research on the use of
parenteral oestrogen in prostate cancer, compared with alternative
treatments, in order to inform the design of a randomised clinical
trial comparing oestrogen patches with LHRH analogues (Abel,
ongoing).
MATERIALS AND METHODS
A systematic review protocol was developed with two principal
aims: firstly, to investigate the clinical effectiveness and safety of
parenteral oestrogen therapy in prostate cancer; and secondly, to
examine any relationship between effectiveness or safety and
oestrogen dose. Eighteen electronic databases, including MED-
LINE, EMBASE and the Cochrane Central Register of Controlled
Trials, were searched from inception to March 2004. Appropriate
published paper and internet resources were also searched. (For a
full list of sources searched and search terms used, see the full
report by Dean et al, 2006.) The searches were updated in
September 2007.
For the first review question, randomised controlled trials
(RCTs) examining parenteral oestrogen in patients diagnosed with
prostate cancer were included. Studies had to report at least one of
the following outcome measures: overall survival, disease-free
survival, disease progression, adverse events, quality of life, and
economic costs. Inclusion criteria for the review question on
dose–response were studies of any design that compared two or
more doses of parenteral oestrogen in patients diagnosed with any
stage of prostate cancer and reported at least one of the outcome
measures listed above. Studies were assessed for inclusion and
quality independently by two reviewers. The methodological
quality of studies was evaluated independently using a modified
form of the Jadad scale (Jadad et al, 1996). Data extraction was
undertaken by one reviewer and independently checked by a
second reviewer. All disagreements were resolved through
consensus, and a third reviewer consulted where necessary.
Multiple publications of a study were collated and extracted as a
single study. No attempt was made to contact authors for missing
data.
RESULTS
Nature of the evidence
The literature search produced 935 citations, from which 75
potentially relevant published papers were obtained. After full
assessment, 22 reports of 17 studies with a total of 3627
randomised patients were included in the review of effectiveness
and safety, and three studies with a total of 82 patients in the
review of dose (Figure 1). Full details of all the studies (including
secondary outcomes not reported here) are available in the CRD
report (Dean et al, 2006). There was considerable variation
between the trials, which differed with regard to the profile of
the patients included, the dose and formulation of parenteral
oestrogen employed, the comparator used; the outcome measures
reported, and the duration of follow-up.
The updated searches produced 541 citations (additional to
those located in the original search), from which 51 additional
potentially relevant published papers were obtained. After full
assessment, three further reports of two previously included
studies were identified in the review of effectiveness and safety
(Mikkola et al, 2005, 2007; Hedlund et al, 2007). Two of these were
full papers (Mikkola et al, 2005, 2007) and one was an abstract
Ongoing studies: update search (n=1)
Studies of dose:
original search 
(n=3)
Studies of effectiveness
and safety: original search
(n=17)
Duplicate studies: original search (n=7) 
update search (n=3)
Potentially relevant studies identified: original search (n=27) 
update search (n=4)
Studies included in systematic review (n=20)
Studies excluded: original search (n=48) 
update search (n=47) 
Citations retrieved for evaluation: original search (n=75) 
update search (n=51) 
Citations excluded: original search (n=860) 
update search (n=490) 
Citations identified: original search (n=935) 
update search (n=541)
Figure 1 Study identification, retrieval and inclusion.
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(Hedlund et al, 2007). In addition, an ongoing trial was identified
that compares transdermal oestrogen administered through
patches with an LHRH analogue, but for which no outcome data
are available (Abel, ongoing). No further studies were identified in
the review of dose.
Therapies and routes of administration Of the 17 studies
included in the review of effectiveness and safety, parenteral
oestrogen was given alone in 9 studies with a total of 2192 patients
(Jacobi et al, 1980; Steg et al, 1983; Bishop et al, 1989; Haapiainen
et al, 1990; Aro et al, 1993; Lukkarinen and Kontturi, 1994;
Mikkola et al, 1998; Henriksson et al, 1999; Hedlund et al, 2002),
combined with oral oestrogen in 7 studies with a total of 1247
patients (Andersson et al, 1980; Daehlin et al, 1986; Haapiainen
et al, 1986; Henriksson and Edhag, 1986; Aro et al, 1988; Johansson
et al, 1991a; Lundgren et al, 1995), and combined with doxorubicin
in 1 study with 188 patients (Leaf et al, 2003). Intramuscular (i.m.)
polyoestradiol phosphate (PEP) was used in 14 of the 17 included
studies (Andersson et al, 1980; Daehlin et al, 1986; Haapiainen
et al, 1986, 1990; Henriksson and Edhag, 1986; Aro et al, 1988,
1993; Bishop et al, 1989; Johansson et al, 1991a; Lukkarinen and
Kontturi, 1994; Lundgren et al, 1995; Mikkola et al, 1998;
Henriksson et al, 1999; Hedlund et al, 2002), and 7 of the 9
studies using parenteral oestrogen alone (Bishop et al, 1989;
Haapiainen et al, 1990; Aro et al, 1993; Lukkarinen and Kontturi,
1994; Mikkola et al, 1998; Henriksson et al, 1999; Hedlund et al,
2002). The other studies used intravenous (i.v.) Stilboestrol (Leaf
et al, 2003), topical 17-b-diethyl-oestradiol (Steg et al, 1983) and
i.m. oestradiol undecylate (Jacobi et al, 1980). The three studies
included in the review of dose all used i.m. PEP alone (Henriksson
et al, 1988; Stege et al, 1988, 1989).
Only one study used any transdermal administration, com-
paring transdermal 17-b-diethyl-oestradiol administered as a
cream with oral Stilboestrol (Steg et al, 1983). This small study
(n¼ 42) was published more than 20 years ago and was poorly
reported. The oestrogen dose of the topical ointment employed
could not be accurately determined. It also used the surrogate
outcome measure of urinary flow to assess tumour response. As
this was the only identified evidence on the use of transdermal
oestrogen, we focused on the higher quality evidence that was
found on the use of i.m. PEP.
Pharmacokinetic studies suggest that a dose of at least
240 mg month1 is required in order to produce sufficient
oestradiol levels to rapidly suppress testosterone to castrate levels,
in a manner similar to orchidectomy (Henriksson et al, 1999).
Of the eight studies employing i.m. parenteral oestrogen alone,
three used PEP doses of 240 mg month1 (Mikkola et al, 1998;
Henriksson et al, 1999; Hedlund et al, 2002), while the remainder
employed 160 mg month1 (Bishop et al, 1989; Haapiainen et al,
1990; Aro et al, 1993; Lukkarinen and Kontturi, 1994) or
100 mg month1 (Jacobi et al, 1980). Seven studies combined
PEP at 80 mg month1 with oral ethinyl oestradiol at 150mg day1
(Andersson et al, 1980; Daehlin et al, 1986; Haapiainen et al, 1986;
Henriksson and Edhag, 1986; Aro et al, 1988; Johansson et al,
1991a; Lundgren et al, 1995), and the remaining study that
assessed parenteral oestrogen in combination used 1 g Stilboestrol
i.v. every 2 weeks with 50 mg m2 doxorubicin every 3 weeks (Leaf
et al, 2003).
Patient populations There were differences between the trial
participants in terms of their disease status, their prior treatment
and their risk of CVS morbidity or mortality, including prior
history of CVS complications. Some studies included only patients
with metastatic disease, while others included only those with
locally advanced prostate cancer. In some trials, there were
stringent exclusion criteria for CVS history, while others did not
exclude anyone on grounds of CVS health. Finally, some trials
included only patients with newly diagnosed prostate cancer, while
in others previous courses of non-hormonal treatment were
permitted. Details of all the studies are presented elsewhere (Dean
et al, 2006). Table 1 presents the study details for those studies
which evaluated parenteral oestrogen alone at a dose of
Table 1 Study details of trials employing PEP at 240 mg monthly
Trial Hedlund et al (2002, 2007) Mikkola et al (1998, 2005, 2007) Henriksson et al (1999)
Study population Advanced (T0–4, Nx, M1, grades 1–3) Locally advanced (T3–4, M0) or metastatic
(T1–4, M1)
Newly detected untreated advanced
Recruitment period December 1992 to June 1997 January 1990 to March 1994 Not reported
Patients recruited
(withdrawn)
917 (7) 444a (not reported) 33 (0)
Disease status T0 (n¼ 5) 0.5%
T1 (n¼ 33) 4%
T2 (n¼ 146) 16%
T3 (n¼ 493) 54% T3 (n¼ 22) 66%
T4 (n¼ n¼ 208) 23% T4 (n¼ 11) 33%
(missing (n¼ 25))
All M1 100% T3–4, M0 (n¼ 244) 55% M0 (n¼ 29) 88%
T1–4, M1 (n¼ 200) 45% M1 (n¼ 4) 12%
G1 (n¼ 136) 15% G1 (n¼ 111) 25%
G2 (n¼ 414) 45% G2 (n¼ 261) 59% G2 (n¼ 20) 61%
G3 (n¼ 340) 40% G3 (n¼ 72) 16% G3 (n¼ 13) 39%
(missing (n¼ 20))
Follow-up Median follow-up: 2 years, subgroup analyses at 3 and 10 years 2 years
PEP 27.1 months
Comparator: 27.4 months, brief report for
12 years
Dose 240 mg every 2 weeks for 2 months
then 240 mg month1
320 mg initial dose then 240 mg month1 240 mg every 2 weeks for 2 months then
240 mg month1
Comparator Orchidectomy or combined androgen ablation Orchidectomy Orchidectomy
Adjuvant therapy No Pretreatment breast irradiation Pretreatment breast irradiation
Cardiovascular criteria No myocardial or cerebral infarct 1 month or
less before the start of study
No symptomatic coronary heart disease Patients with previous cardiovascular
disease were included
Study quality High Randomisation poorly reported Randomisation poorly reported
PEP¼ polyoestradiol phosphate. aIt is not clear whether this is the total number recruited to the study or whether it is the number of patients reported as being in the study.
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Table 2 Included studies assessing parenteral oestrogen alone
Study N Comparator Follow-up All-cause mortality
Prostate cancer
mortality
Cardiovascular adverse
events Study quality
PEP at 240 mg monthlya
Hedlund et al
(2002, 2007)
917 Comparator: triptorelin
3.75 mg month1
i.m.+flutamide 250 mg
t.i.d., p.o. (n¼ 298)
or optionally
orchidectomy
(n¼ 159)
Median:
PEP: 27.1 months
Comparator: 27.4
months (brief report at
12 years)
PEP: 277/455 (60.9%)
Comparator: 279/455
(61.3%)
PEP: 239/455 (52.5%)
Comparator: 252/455
(55.4%)
PEP: 80/455 (17.6%),
23 fatal (5.1%)
Comparator: 59/455 (13.0%),
23 fatal (5.1%)
High quality, blind outcome
assessment, central
randomisation
Mikkola et al
(1998, 2005,
2007)
444 Orchidectomy 2 years; subgroup
analyses at 3 and 10
years
2 years:
PEP: 27/227 (11.9%)
2 years:
PEP: 8/227 (3.5%)
2 years:
PEP: 24/227 (10.6%),
14 fatal (7.5%)
Adequate study design but
inadequate reporting of
withdrawalsOrchidectomy: 23/217
(10.6%)
Orchidectomy: 7/217
(3.2%) Orchidectomy: 10/217 (4.6%),
5 fatal (2.3%)10 years:
M0: PEP: 97/125
(77.6%)
Orchidectomy: 88/119
(73.9%)
M1: PEP: 94/102
(92.2%)
Orchidectomy: 91/98
(92.9%)
10 years: M0: PEP: 44/125
(35.2%) Orchidectomy: 47/
119 (39.5%);
M1: PEP: 76/102 (74.5%)
Orchidectomy: 61/98
(62.2%)
Mortality at 10 years: M0: PEP:
28/125 (22.4%) Orchidectomy:
13/119 (10.9%);
M1: PEP: 11/102 (10.8%)
Orchidectomy: 12/98 (12.2%)
Henriksson et al
(1999)
33 Orchidectomy 2 years PEP: 0/17 (0%)
Orchidectomy: 1/16
(6.2%)
Not reported PEP: 1/17 (5.9%)
Orchidectomy: 4/16 (25.0%)
Pilot study, method of
randomisation not
described
PEP at 160 mg monthlya
Lukkarinen and
Kontturi (1994)
236 LHRH: goserelin s.c.
depot injection 3.6 mg
per 28 days
Mean:
PEP: 23 months
LHRH: 26 months
PEP: 13/107 (12.1%)
LHRH: 14/129 (10.8%)
PEP: 3/107 (2.8%)
LHRH: 3/129 (2.3%)
PEP: 23/107 (21.5%),
7 fatal (6.5%)
LHRH: 13/129 (10.1%),
8 fatal (6.2%)
Inadequate reporting of
withdrawals
Haapiainen et al
(1990)
200 Orchidectomy 42 years PEP: 12/125 (9.6%)
Orchidectomy: 6/75
(8.0%)
PEP: 6/125 (4.8%)
Orchidectomy: 5/75 (6.7%)
CVS mortality:
PEP: 2/125 (1.6%)
Orchidectomy: 1/75 (1.3%)
Inadequate reporting of
withdrawals
Non-fatal events NR
Aro et al (1988,
1989, 1993)
147 LHRH: buserelin 6.6 mg
per 8 weeks; implant
s.c.
3 years NR NR PEP: 5/70 (7.1%), 4 fatal (5.7%)
LHRH: 6/77 (7.8%), 4 fatal
(5.2%)
Adequate study design
Bishop et al
(1989)
117 Orchidectomy NR NR NR PEP: 8/61 (13.1%), 3 fatal
(4.9%)
Insufficient information to
assess
Orchidectomy: 4/56 (7.1%),
all fatal
Oestradiol undecylate at 100 mg monthly
Jacobi et al
(1980)
42 Cyproterone acetate
300 mg week1 i.m.
NR NR NR PEP: 16/21 (76.2%),
2 fatal (9.5%)
Insufficient information to
assess
Cyproterone: 0/21 (0%)
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240 mg month1. It shows the variation in the patient populations
between the studies, for example, all patients in the Hedlund trial
had metastatic disease (Hedlund et al, 2002), compared with 45%
in the Mikkola trial (Mikkola et al, 1998) and 12% in the
Henriksson trial (Henriksson et al, 1999).
Study quality None of the studies met all of the quality criteria;
the majority of the studies were not reported in sufficient detail to
allow full assessment of their methodological quality (Dean et al,
2006). In particular, the methods of randomisation and blinding
were rarely described; only two reports contained enough detail to
confirm that the method of randomisation was appropriate (Aro
et al, 1993; Hedlund et al, 2002), one of which also reported that
randomisation was concealed (Aro et al, 1993). Only one study
reported that cardiovascular outcomes were assessed by a
cardiologist blinded to the interventions (Hedlund et al, 2002).
Trials using PEP at 240 mg month1
In this report, emphasis is given to the three studies, including a
total of 1394 patients, that used PEP at the biological minimally
effective dose. The results of these studies are given in Table 2. The
largest most recent study (n¼ 917) was of good quality (Hedlund
et al, 2002). This study randomised patients with T0-4 NX M1
prostate cancer to either PEP twice a month for 2 months and
thereafter monthly, or to combined androgen blockade (flutamide
and LHRH analogue or on an optional basis bilateral orchidect-
omy). A second study (n¼ 444), by Mikkola et al (2007, 1998),
randomised patients with T3-4 M0 or T1-4 M1 prostate cancer to
either PEP or orchidectomy, and this study was of reasonable
quality. The third study was a small phase II study, which
randomised patients with newly diagnosed advanced prostate
cancer to either PEP or orchidectomy (Henriksson et al, 1999).
Overall mortality The Hedlund study had high overall mortality
(7 years after the start of the trial, with a median follow-up of 27
months, 61% of all patients had died) (Hedlund et al, 2002). There
was no evidence of any difference in overall mortality between the
treatment groups (RR¼ 0.99, 95% CI: 0.90, 1.10; P¼ 0.89)
(Figure 2). This finding was confirmed by a brief report of a
subsequent evaluation of data at 12-year follow-up, at which point
94% of patients had died (Hedlund et al, 2007). In the Mikkola
trial, 76% of M0 and 93% of M1 patients had died at 10-year
follow-up (Mikkola et al, 2007). The 2-year evaluation found no
evidence of a difference in overall mortality between the treatment
groups (RR¼ 1.12, 95% CI: 0.66, 1.90; P¼ 0.67) (Mikkola et al,
1998). Subgroup analysis using a Cox proportional hazards model
at 10-year follow-up also showed no evidence of a difference
between the PEP and the orchidectomy arm in either the M0 or the
M1 patients (M0: RR¼ 1.23, 95% CI: 0.92, 1.64; P¼ 0.17; M1:
RR¼ 0.95, 95% CI: 0.70, 1.27; P¼ 0.70) (Mikkola et al, 2007). The
RRs calculated from raw data presented in the publication are
shown in Figure 3. The Henriksson trial reported only one death in
the orchidectomy group and none in the PEP group (Henriksson
et al, 1999).
Prostate cancer mortality The majority of mortality in the
Hedlund study was reportedly due to prostate cancer; there was
no evidence of any difference between treatment groups in the
occurrence of cancer deaths (RR¼ 0.95, 95% CI: 0.84, 1.07;
P¼ 0.39) (Hedlund et al, 2002) (Figure 4). This finding was
confirmed by a brief report of a subsequent evaluation (Hedlund
et al, 2007). There was also no evidence of a difference in prostate
cancer mortality in the two arms of the Mikkola trial at 2 years
(RR¼ 1.09, 95% CI: 0.40, 2.96; P¼ 0.86) (Mikkola et al, 1998);
subsequent subgroup analysis using a Cox proportional hazards
model at 10-year follow-up also showed no difference in disease-
specific mortality in either M0 or M1 patients (M0: RR¼ 1.14, 95%Ta
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CI: 0.75, 1.73; P¼ 0.55; M1: RR¼ 1.07, 95% CI: 0.76, 1.50; P¼ 0.72)
(Mikkola et al, 2007). RRs calculated from raw data presented in
the publication are shown in Figure 3. The small study by
Henriksson et al (1999) reported no deaths due to prostate cancer.
CVS mortality There was no evidence of a difference in CVS
mortality in the Hedlund trial (RR¼ 1.00, 95% CI: 0.57, 1.76;
P¼ 1.00) (Hedlund et al, 2002) (Figure 4). This finding was
confirmed by a brief report of a subsequent evaluation (Hedlund
et al, 2007). The Mikkola trial showed an increased level of CVS
mortality in the PEP arm, although this was of borderline statistical
significance (RR¼ 2.68, 95% CI: 0.98, 7.31; P¼ 0.05) (Mikkola
et al, 1998). Subsequent subgroup analyses using a Cox propor-
tional hazards model found this increase to be confined to M0
patients (RR¼ 3.52, 95% CI: 1.65, 7.54; P¼ 0.001); the subgroup
with M1 disease showed no difference between the PEP and the
orchidectomy groups (RR¼ 0.92, 95% CI: 0.36, 2.36; P¼ 0.86)
(Mikkola et al, 2007). RRs calculated from raw data presented in
the publication are shown in Figure 3. In this study, the authors
retrospectively classified patients into those at high risk of CVS
complications due to pretreatment vascular disease (patients with
previous coronary heart disease, cerebral infarction, transient
ischaemic attack or intermittent claudication), those with other
pretreatment diseases associated with the risk of CVS events
(patients with previous diabetes mellitus, hypertension, cardiac
heart failure or rheumatoid arthritis), and those without any of the
above pretreatment diseases (Mikkola et al, 2005). Within both the
M0 and the M1 patient groups, the proportional hazards model
found that the excess mortality in the PEP treatment arm was
higher in those classified as having pretreatment vascular disease
(M0: RR¼ 3.48, 95% CI: 1.63, 7.44; P¼ 0.001; M1: RR¼ 3.13, 95%
CI: 1.09, 9.00; P¼ 0.035), but those with other pretreatment disease
associated with CVS risk did not have significantly increased
mortality (M0: RR¼ 1.64, 95% CI: 0.59, 4.57; P¼ 0.34; M1:
RR¼ 1.63, 95% CI: 0.40, 6.57; P¼ 0.49) (Mikkola et al, 2007).
There were no CVS deaths reported in the Henriksson trial
(Henriksson et al, 1999).
CVS morbidity In contrast to the evidence on mortality, it
appeared that CVS morbidity may occur at an increased rate in the
PEP groups. In the Hedlund trial, this difference was statistically
significant (RR¼ 1.58, 95% CI: 1.07, 2.35; P¼ 0.02) (Hedlund et al,
2002) (Figure 5). In particular, the incidence of both ischaemic
heart disease (RR¼ 3.40, 95% CI: 1.27, 9.14; P¼ 0.02) and heart
decompensation (RR¼ 2.22, 95% CI: 1.02, 4.83; P¼ 0.04) was
significantly higher in the PEP arm. This finding was confirmed by
a brief report of a subsequent evaluation (Hedlund et al, 2007). The
Mikkola trial also initially reported higher levels of CVS morbidity
in the PEP arm than the orchidectomy arm, but this difference was
not statistically significant (RR¼ 1.91, 95% CI: 0.66, 5.50; P¼ 0.23)
(Mikkola et al, 1998). However, subsequent subgroup analyses at
36-month follow-up revealed that there was a significantly greater
incidence of CVS complications, including mortality, in the M0
patients (RR¼ 3.40, 95% CI: 1.34, 8.59; P¼ 0.01) but not in the M1
patients (RR¼ 1.55, 95% CI: 0.61, 3.97; P¼ 0.36) (Mikkola et al,
2005). As with CVS mortality, a Cox proportional hazards model
RR (fixed) 
95% CI
RR (fixed) 
95% CI
Comparator
n/N
PEP
n/N
Study
PEP 240 mg vs LHRH/orchidectomy
Hedlund et al (2002)      277/455             279/455      0.99 (0.90, 1.10)
PEP 240 mg vs orchidectomy
Mikkola et al (1998)       27/227              23/217      1.12 (0.66, 1.90)
PEP 160 mg vs LHRH
Lukkarinen and Kontturi (1994)      13/107              14/129      1.12 (0.55, 2.28)
PEP 160 mg vs orchidectomy
Haapiainen et al (1990)       12/125                6/75      1.20 (0.47, 3.06)
0.1 0.2 0.5 1 2 5 10
Favours PEP Favours comparator
Figure 2 Overall mortality. Trials included in the figure are those where the parenteral oestrogen was PEP alone and for which data were fully reported. It
should be noted that the follow-up times reported were not entirely uniform; where data for multiple time points were available those closest to 2 years are
presented. Trials with zero events in any arm are not included in the figure.
Mikkola et al (2007) overall mortality
MO patients
M1 patients
      97/125              88/119      1.05 (0.91, 1.21)
      94/102               91/98      0.99 (0.92, 1.07)
Mikkola et al (2007) cardiovascular mortality
MO patients
M1 patients
Mikkola et al (2007) prostate cancer mortality
MO patients
M1 patients
      28/125              13/119      2.05 (1.12, 3.77)
      11/102               12/98      0.88 (0.41, 1.90)
      44/125              47/119      0.89 (0.64, 1.23)
      76/102               61/98      1.20 (0.99, 1.45)
0.2 0.5 1 2 5
Favours PEP Favours comparator
RR (fixed) 
95% CI
RR (fixed) 
95% CI
Comparator
n/N
PEP
n/N
Study
Figure 3 Overall, CVS and prostate cancer mortality at 10-year follow-up in the Mikkola trial for M0 and M1 subgroups. RRs shown are calculated from
raw data presented in the publication and differ from those reported in the text, which were extracted from the Cox proportional hazards model reported.
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found that the complication rate was significantly increased in
those M0 patients with pretreatment vascular disease (RR¼ 4.71,
95% CI: 1.69, 13.09; P¼ 0.003), but not in those with other
pretreatment disease associated with CVS risk (RR¼ 2.25, 95% CI:
0.65, 7.83; P¼ 0.20) (Mikkola et al, 2005). The Henriksson trial
found more events in the orchidectomy group (4 out of 16) than in
the PEP group (1 out of 17) (Henriksson et al, 1999).
Trials using lower doses of parenteral oestrogen alone
Five trials used PEP or a similar preparation at 160 or
100 mg month1. The results are shown in Table 2. There was no
evidence of a statistically significant difference between treatment
groups in either overall or prostate cancer mortality in the two
studies that reported these outcomes. Cardiovascular mortality
was reported by all five trials and did not differ significantly
between treatment groups in any of the trials (P-values ranged
from 0.29 to 0.91). Cardiovascular morbidity was reported in four
trials (Jacobi et al, 1980; Bishop et al, 1989; Aro et al, 1993;
Lukkarinen and Kontturi, 1994), and in only one, there was a
statistically significant increase in the PEP group compared to the
LHRH group (RR¼ 3.86, 95% CI: 1.46, 10.19; P¼ 0.01) (Lukkarinen
and Kontturi, 1994).
Trials using parenteral oestrogen combined with oral
oestrogen or doxorubicin (PEPþ )
Seven trials with a total of 1256 patients used PEP (i.m.) at
80 mg month1 in combination with 150mg day1 oral oestradiol
(Andersson et al, 1980; Daehlin et al, 1986; Haapiainen et al, 1986;
Henriksson and Edhag, 1986; Aro et al, 1988; Johansson et al,
1991a; Lundgren et al, 1995). One trial with 188 patients used
Stilboestrol i.v. in combination with doxorubicin (Leaf et al, 2003).
The results are given in Table 3. There was no evidence of a
statistically significant difference between treatment groups in
overall, prostate cancer or cardiovascular mortality in any of the
studies that reported these outcomes. However, cardiovascular
morbidity was higher in the PEPþ group than the comparator
group for a number of studies; in particular, in one trial,
recruitment to the PEPþ arm was terminated early due to the
high number of cardiovascular events (Lundgren et al, 1995).
Dose
Three studies with a total of 82 patients examined different doses
of PEP (Henriksson et al, 1988; Stege et al, 1988, 1989). All were
small and of uncertain or poor quality; one was a non-randomised
trial (Henriksson et al, 1988). None of the studies reported
mortality and in none of the studies any CVS events were reported
(Table 4).
DISCUSSION
This review of effectiveness and safety focused on the randomised
evidence related to the use of i.m. PEP; only one small poor quality
study of transdermal oestrogen cream was identified. The included
trials were generally poorly reported or of poor quality. Nine
studies evaluated parenteral oestrogen administered as mono-
therapy, and three of these used a clinically relevant dose of PEP
PEP 240 mg vs LHRH/orchidectomy
Hedlund et al (2002)       57/455              36/455      1.58 (1.07, 2.35)
PEP 240 mg vs orchidectomy
Mikkola et al (1998)
Henriksson et al (1999)
      10/227               5/217      1.91 (0.66, 5.50)
        1/17                4/16      0.24 (0.03, 1.89)
PEP 160 mg vs LHRH
Lukkarinen and Kontturi (1994)
Aro et al (1993)
      16/107               5/129      3.86 (1.46, 10.19)
        1/70                2/77      0.55 (0.05, 5.93)
RR (fixed) 
95% CI
RR (fixed) 
95% CI
Comparator
n/N
PEP
n/N
Study
0.1 0.2 0.5 1 2 5 10
Favours PEP Favours comparator
Figure 5 CVS morbidity. Trials included in the figure are those where the parenteral oestrogen was PEP alone and for which data were fully reported. It
should be noted that the follow-up times reported were not entirely uniform; where data for multiple time points were available those closest to 2 years are
presented. Trials with zero events in any arm are not included in the figure.
PEP 240 mg vs LHRH/orchidectomy
Hedlund et al (2002)       23/455             23/455      1.00 (0.57, 1.76)
PEP 240 mg vs orchidectomy
Mikkola et al (1998)       14/227              5/217      2.68 (0.98, 7.31)
PEP 160 mg vs LHRH
Lukkarinen and Kontturi (1994)
Aro et al (1993)
       7/107              8/129      1.05 (0.40, 2.81)
        4/70               4/77      1.10 (0.29, 4.23)
PEP 160 mg vs orchidectomy
Haapiainen et al (1990)
Bishop et al (1989)
       2/125               1/75      1.20 (0.11, 13.01)
        3/61               4/56      0.69 (0.16, 2.94)
RR (fixed) 
95% CI
RR (fixed) 
95% CI
Comparator
n/N
PEP
n/N
Study
Favours PEP Favours comparator
0.1 0.2 0.5 1 2 5 10
Figure 4 CVS mortality. Trials included in the figure are those where the parenteral oestrogen was PEP alone and for which data were fully reported. It
should be noted that the follow-up times reported were not entirely uniform; where data for multiple time points were available those closest to 2 years are
presented. Trials with zero events in any arm are not included in the figure.
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Table 3 Included studies assessing parenteral oestrogen in combination with oral oestrogen or doxorubicin (PEP+)
Study N Comparator Follow-up All-cause mortality
Prostate cancer
mortality
Cardiovascular adverse
events Study quality
PEP at 80 mg monthly plus oral ethinyl oestradiol at 150 mg daily (PEP+)a
Lundgren et al
(1995)
285 (1) Estramustine phosphate
280 mg b.i.d., p.o.
(2) Surveillance, endocrine
treatment on progression
X9 years PEP+: 35/66 (53.0%)
Estramustine: 40/74 (54.1%)
Surveillance: 53/88 (60.2%)
PEP+: 8/66 (12.1%)
Estramustine: 13/74
(17.6%)
Surveillance: 25/88 (28.4%)
Events leading to withdrawal:
PEP+: 37/66 (56.1%)
Estramustine: 30/74 (40.5%)
Surveillance: 11/88 (21.5%)
Large number of patients
withdrawn and excluded from
analysis. Recruitment to PEP+
arm terminated early due to
high CVS event rate
Haapiainen et al
(1986, 1991)
277 Orchidectomy 5 years PEP+: 101/146 (69.1%)
Orchidectomy: 86/131 (65.6%)
PEP+: 45/146 (30.8%)
Orchidectomy: 47/131
(35.9%)
CVS mortality:
PEP+: 35/146 (24.0%)
Orchidectomy: 24/131 (18.3%)
Inappropriate randomisation
(by date of birth)
Andersson et al
(1980)
263 Estramustine phosphate
840 mg day1 b.i.d., p.o.
X2 years NR NR No significant difference
between groups (values not
reported)
Trial groups not clearly
explained
Aro et al (1988) 151 (1) Orchidectomy
(2) Radiotherapy 40 Gy
(whole pelvis), 26 Gy (prostate)
over 9 weeks including
3 weeks rest
4 years PEP+: 16/50 (32.0%)
Orchidectomy: 23/56 (41.1%)
Radiotherapy: 9/45 (20.0%)
NR PEP+: 18/50 (36.0%), 5 fatal
(10%)
Orchidectomy: 13/56 (23.2%),
6 fatal (10.7%)
Radiotherapy: 6/45 (22.2%),
3 fatal (11.1%)
Inappropriate randomisation
(date of birth)
Johansson et al
(1991a, b)
150 Orchidectomy 7–10 years
(5 years for survival
data)
PEP+: 54/74 (73.0%)
Orchidectomy: 54/76 (71.1%)
PEP+: 27/74 (36.5%)
Orchidectomy: 36/76
(47.4%)
PEP+: 36/74 (48.6%), 13 fatal
(17.6%)
Orchidectomy: 13/76 (17.1%),
9 fatal (11.8%)
Inappropriate randomisation
(date of birth)
Henriksson and
Edhag (1986);
Henriksson and
Johansson (1987)
91/100 Orchidectomy X1 year NR NR Major CVS events
PEP+: 13/53 (24.5%)
Orchidectomy: 0/47 (0%)
9 non-randomised patients
included
Daehlin et al (1986) 30 (1) Estramustine phosphate
9.2 mg kg1 day1 b.i.d., p.o
(2) Orchidectomy
6 months NR NR PEP+: 1/10 (10%), 0 fatal (0%)
Estramustine phosphate: 3/10
(30%), 1 fatal (10%)
Orchidectomy: 0/10 (0%)
Insufficient information to
assess
1 g Stilboestrol i.v. every 2 weeks plus 50 mg m2 doxorubicin every 3 weeksa
Leaf et al (2003) 188 Doxorubicin 50 mg m2
every 3 weeks
45 years Median survival:
PEP+: 8.5 months
Doxorubicin: 7.7 months
NR PEP+: 13.5%, 1.4% fatal
Doxorubicin: 1.3%, 0% fatal
Insufficient information to
assess
CVS¼ cardiovascular system; N¼ number of patients; NR¼ not reported; PEP¼ polyoestradiol phosphate; PEP+¼ PEP combined with oral oestrogen. Studies are ordered by sample size within dosage categories. Since increased
cardiovascular risk occurs primarily during the first 2 years of oestrogen therapy, where trials report CVS events for more than one follow-up period, those closest to 2 years are given. aIn some trials, participants may have had higher
initial treatment doses or may have received other additional treatment. The dose given here is the routine dose given for the duration of the trial. Further details can be found in the full evidence tables (see Appendix 7 of CRD
report).
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(240 mg month1), including two large recent RCTs, one of
which was of good methodological quality. There was variation
in the patient populations of these three studies, in particular,
the proportion of patients with metastatic disease (all patients in
the Hedlund trial had metastatic disease compared to less than half
of patients in the Mikkola trial). The comparator arm was a mixed
LHRH/orchidectomy arm in the Hedlund trial and orchidectomy
alone in the other two trials. In addition, the analysis in the
Mikkola trial was based on 10-year follow-up, although some data
from 2-year follow-up were also included in the review. The
Hedlund trial analysis was based on patients who had died within
7 years after the start of the trial with a median follow-up of 27
months; although data at 12-year follow-up have now been
analysed, the report is currently only available in abstract form.
A 24-month follow-up was reported in the Henriksson trial. Given
the variation in study populations and outcomes, it was decided
that it would not be meaningful to statistically pool these studies.
Effectiveness
The randomised trials included in the review provided no clear
evidence that parenteral oestrogen alone, at doses sufficient to
produce castrate levels of testosterone, differed in effectiveness
from LHRH analogues or orchidectomy in terms of prostate cancer
mortality or overall mortality.
Adverse events
The included studies also provided no consistent evidence that the
incidence of fatal cardiovascular events with parenteral oestrogen
alone is different to that reported with LHRH analogues or
orchidectomy. Where there is evidence of excess mortality, the
data suggest that it may be confined to those patients who have
non-metastatic disease and to patients with pretreatment vascular
disease; patients with other pretreatment disease associated with
the risk of CVS events do not appear to incur a similar risk for
excess mortality with PEP therapy (but the exclusion of,
for example, hypertension and cardiac heart failure as high risk
for CVS events may be considered contentious). However, there is
clearer evidence of increased cardiovascular morbidity with
parenteral oestrogen alone, although the seriousness of non-fatal
adverse events was often not reported and criteria for recording an
event were often unclear.
Such CVS risks should be balanced against the risks of non-CVS
adverse events resulting from LHRH analogues or orchidectomy
such as osteoporosis and osteoporotic fracture; these were
reported in only one of the trials included in the review, which
did show an increased rate of skeletal adverse events in the
combined ADT arm (Hedlund et al, 2007). Other potential adverse
events of LHRH analogues were not reported in any of the
included studies. This lack of evidence on adverse events
associated with standard hormone treatment may result partly
from the relatively short follow-up times used in many of the
studies, but also suggests that such events were not considered in
the study design. Standard hormone treatment results in high
levels of osteoporosis and, consequently, of osteoporotic fracture
with a mortality rate of approximately 15% in the first year,
although this has been reported to be as high as 35% (Center et al,
1999). Incidence of osteoporotic fracture should be an outcome
measure for safety in any future trial.
Long-term follow-up is also of importance in risk assessment,
given that there are indications that the effect of parenteral
oestrogen on the incidence of CVS events may not be monotonic.
For women on hormone replacement therapy, increased CVS risk
over the first 2 years has been observed. Thereafter, CVS benefit
accrues, such that the risk of CVS events is reduced by 30– 50%
after 10 years on treatment (Hulley et al, 1998; Grodstein et al,
2001). Similar changes may occur in men (Aro, 1991; Ockrim JL
et al, 2006). This pattern of risk may result from changes in arterial
compliance caused by oestrogen therapy. During the early months
of oestrogen therapy, arterial compliance is reduced and cardiac
demands increased. Thereafter, arterial compliance adapts leading
to improved CVS dynamics (Turgeon et al, 2004). However, the
Mikkola study examined the incidence of CVS events and found
that the rate of occurrence did not diminish significantly over the
first 3 years of treatment. Instead, the risk remained higher among
men with non-metastatic disease in the PEP group than in the
orchidectomy group, but did not differ between groups for those
with metastatic disease (Mikkola et al, 2005).
Costs
No economic evaluations were found. In addition to the cost of
treatment regimes, the economic impact of the adverse events
associated with alternative treatments requires evaluation. The
annual cost of osteoporotic fractures in men in the United
Kingdom has been estimated at d236 million (Pande and Francis,
2001). A previous economic evaluation of LHRH analogues has
indicated that they are a cost-effective alternative to orchidectomy,
but this is a hormonally equivalent treatment, which also results in
Table 4 Included studies comparing parenteral oestrogen given at different doses
Study N Comparator Follow-up
All-cause
mortality
Prostate
cancer
mortality
Cardiovascular
adverse events Study quality
PEP at 320 mg monthly
Henriksson et al
(1988)
38 PEP i.m. Mean: 14.1
months
NR NR 0 in all groups Non-randomised trial
(1) 240 mg month1
(2) 160 mg month1
Stege et al
(1988)
27 PEP i.m. 6 months NR NR 0 in all groups Insufficient information
to assess(1) 240 mg month1
(2) 160 mg month1
PEP at 320 mg monthly for 6 months reducing to 160 mg monthly for 6 months
Stege et al
(1989)
17 PEP i.m. 320 mg month1 for
6 months then 80 mg month1
for 6 months
NR NR NR 0 in both arms Insufficient information
to assess
N¼ number of patients; NR¼ not reported; PEP¼ polyoestradiol phosphate. Studies are ordered by sample size within dosage categories.
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the andropause (Aronson et al, 1999). A subsequent evaluation
indicated that LHRH-based therapy was more cost-effective than
orchidectomy or DES if initiated only after development of
metastases (Bayoumi et al, 2000). One estimate suggests that
hormonal therapy accounts for more than two-thirds of the total
cost of prostate cancer, approximately d63.1 million for patients
diagnosed during 2001–2002 in the United Kingdom (Sangar et al,
2005). These costs increase substantially with the addition of anti-
androgens or bisphosphonates. In contrast, oestrogen patches cost
approximately one-tenth the price of LHRH analogues (Ockrim J
et al, 2006). Alternative transcutaneous administration using
cream or gel is likely to be comparable in cost to that of patches.
CONCLUSION AND FUTURE RESEARCH
Because of the paucity of good quality evidence, it is not possible to
draw any clear conclusion on the effectiveness and safety of
parenteral oestrogen compared with other hormone therapy. The
results of this systematic review provide no evidence to suggest that
parenteral oestrogen, in doses sufficient to produce castrate levels of
testosterone, is less effective than LHRH or orchidectomy in
controlling prostate cancer, or that it is associated with an increase
in cardiovascular mortality. There is, therefore, a need for further
research into the use of parenteral oestrogen as an alternative to
existing hormone treatments for prostate cancer, which are
associated with a number of side effects and high costs. Evaluation
of parenteral oestrogen, involving direct comparison of the adverse
event profile with that of LHRH analogues including, but not limited
to, osteoporotic events, is needed. Particular attention should be
paid to the issue of clearly defining and accurately assessing
cardiovascular morbidity as well as mortality, especially in relation
to a patient’s existing cardiovascular disease status, particularly
their history of vascular disease, and the metastatic status of their
prostatic cancer. Patients’ acceptability and quality of life issues
should also be examined, along with a full economic evaluation. A
pilot RCT of transcutaneous oestrogen patches vs LHRH analogues
in prostate cancer is currently underway (Abel, ongoing). The
primary objective of this study is to confirm that oestrogen patches
are a safe and efficacious therapy for patients with locally advanced
and metastatic prostate cancer.
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